Oral Semaglutide Shows Promise in Adolescents with Type 2 Diabetes

Novo Nordisk has reported positive topline results from the Phase 3a PIONEER TEENS trial¹ evaluating oral semaglutide in children and adolescents aged 10 to 17 years with type 2 diabetes.

The study demonstrated a statistically significant reduction in hemoglobin A1c (HbA1c) of 0.83% compared with placebo at 26 weeks, meeting its primary endpoint. The therapy also showed a safety and tolerability profile consistent with previous semaglutide trials in adults.

Oral semaglutide is currently marketed as Rybelsus and is expected to launch in the United States as Ozempic pill. The company plans to submit for regulatory approval of a label expansion in both the US and EU later this year.

Addressing a Growing Pediatric Health Burden

Type 2 diabetes in children and adolescents is a progressive disease associated with long-term complications and increased risk of early mortality.

Despite rising prevalence, treatment options remain limited.

Current standard-of-care therapies include metformin and insulin, both of which present challenges. Metformin is associated with glycemic control failure in a substantial proportion of adolescents, while insulin therapy can lead to hypoglycemia and weight gain.

Against this backdrop, the PIONEER TEENS trial represents the first evaluation of an oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) in this age group, potentially expanding the therapeutic landscape.

Trial Design and Key Findings

The PIONEER TEENS study was a 52-week, randomized, double-blind, placebo-controlled trial involving 132 participants aged 10 to 17 years with type 2 diabetes. Patients received oral semaglutide at doses of 3 mg, 7 mg, or 14 mg once daily, in addition to background therapy with metformin, basal insulin, or both.

The primary endpoint assessed change in HbA1c from baseline to week 26. Results showed superior glycemic control with oral semaglutide compared with placebo, supporting its potential clinical utility in this population.

Mechanism and Broader Clinical Context

Semaglutide is a GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon levels, and slows gastric emptying, contributing to improved blood glucose control. In adult populations, the therapy has also demonstrated benefits in weight reduction and cardiovascular risk reduction.

If approved for pediatric use, oral semaglutide could represent a shift toward non-injectable GLP-1 therapies in younger patients, offering a more convenient administration option compared with injectable biologics.

Regulatory Outlook and Future Implications

Novo Nordisk indicated it expects to file for regulatory approval of oral semaglutide in pediatric patients in the second half of the year. If authorized, the therapy could become the first oral GLP-1 receptor agonist approved for children and adolescents with type 2 diabetes.

The development reflects a broader industry trend toward expanding incretin-based therapies into earlier stages of disease and younger populations, as well as increasing focus on patient-friendly formulations.

References

• A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (PIONEER TEENS). National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04596631
• Bensignor, M. O., Hsia, D. S., Van Name, M. A., Jastreboff, A. M., & Ryder, J. R. (2025 Jul 29). Extinguishing the fire: Treating pediatric type 2 diabetes by targeting obesity treatment. PubMed Central. https://doi.org/10.2337/dci25-0031